Gain Therapeutics, Inc.
Gain Therapeutics, Inc. (GANX) is a publicly traded company in the Unknown sector. Across all available filings, 6 corporate insiders have executed 21 transactions totaling $24.6M, demonstrating a bullish sentiment with $24.6M in net insider flow. The most recent transaction on Aug 9, 2024 involved a purchase of 14,400 shares valued at $14.5K.
GANX Insider Activity Summary
Who Is Buying GANX Stock?
No significant insider buying has been recorded for GANX in the recent period.
Who Is Selling GANX Stock?
No significant insider selling has been recorded for GANX in the recent period.
Is Gain Therapeutics, Inc. Insider Trading Bullish or Bearish?
Based on recent SEC filings, insider sentiment for GANX is bullish with an Insider Alignment Score of 100/100 and a net flow of $24.6M. Insiders are accumulating shares, which historically signals confidence in the company's future performance.
GANX Frequently Asked Questions
Understanding GANX Insider Activity
Insider trading at Gain Therapeutics, Inc. (GANX) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of the company's shares. These individuals have access to material non-public information and are required by law to report their trades to the SEC within two business days. Currently, 6 insiders are actively trading GANX stock, having executed 21 transactions in the past 90 days. The most active insider is Salvatore Calabrese (Executive), who has made 2 transactions totaling $24.3M.
Related Tools
Track Gain Therapeutics, Inc. Insider Activity
Get notified when executives and directors at GANX file new Form 4 transactions